Final Program

Day 1 (Hepatitis Day)
A New Era in Viral Hepatitis

 7.30-17.00 Registration

8.30-8.40 Wellcome

Plenary session 1
The current standard-of-care triple therapy for genotype-1 infected patients
Chair: Mircea Grigorescu, Vlad Ratziu, Anca Trifan

8.40-8.55 Global epidemiology, detection and access to therapy in Europe
Ioan Sporea, Romania

8.55-9.10 How to optimize triple therapy with 1st generation of protease inhibitors in genotype-1 patients
Adrian Goldis, Romania

9.10-9.25 How to manage side effects of triple therapy with 1st generation of protease inhibitors
Marina Maevskaya, Russia

9.25-9.40 Who should be treated now and who can wait
Iulia Simionov, Romania

9.40-10.00 Discussion

10.00-10.20 Coffee break

Plenary session 2
New antiviral regimens on horizon: How should we treat hepatitis C starting with 2015
Chair: Liana Gheorghe, Simona Ruta, Susanne Beckebaum

10.20-10.35 Hepatitis C – a virological perspective
Simona Ruta, Romania

10.35-10.50 New antiviral therapy in special populations: liver cirrhosis and liver transplant recipients
Susanne Beckebaum, Germany

10.50-11.05 Predictive factors of virological response to  triple therapy
Bela Hunyady, Hungary

11.05-11.20 Advantages of the 2nd generation of IFN-based triple therapy
Anca Trifan, Romania

11.20-11.40 IFN-free regimens: protease, polymerase and NS5A inhibitors – the cocktail of the future
Vlad Ratziu, France

11.40-12.00 Discussion

12.00-13.30 Lunch

12.00-13.30 Luncheon sessions with experts (limited places available)

WORKSHOP 1 (30 places available)
Transilvania Room 
From trials to clinical practice in antiviral therapy for hepatitis C – current critical points in patients management (patients’ selection and monitoring during therapy, response assessment, management of adverse events)
Chairs: Vlad Ratziu, Speranta Iacob

WORKSHOP 2 (20 places available)
Moldova Room
Antiviral therapy of HBV infection – whom, when and how to treat
Chairs: Ferruccio Bonino, Mircea Diculescu

Interactive plenary session 3 (Experts & Participants)
Facing new waves of antivirals for hepatitis C : a strategy for middle- and low-income countries
Chair: Alexandru Oproiu
Experts:  Ioan Sporea, Bela Hunyady, Jerzy Jaroszewski, Marina Maevskaya,  Anca Trifan, Mircea Diculescu, Liana Gheorghe, 

Part I Collecting the Central & East European Experts Opinion (Carol Stanciu)

Introduction (Carol Stanciu)
· A critical overview of current guidelines
Ioan Sporea (10 min)
· How has Hungary solved the problem of
access to reimbursed DAA therapy?
Béla Hunyady (10 min)
· How has Poland solved the problem of
access to reimbursed DAA therapy?
Jerzy Jaroszewicz (10 min)
· DAA therapy in limited-budget settings – ethical, medical, and economic aspects
Oliviu Pascu (10 min)

Part 2 Critical questions, General discussion and Voting
(Oliviu Pascu, Alexandru Oproiu)

(8-10 critical questions in perspective of DAA
therapy for hepatitis C in Romania will be discussed and voted giving the opportunity of a Professionals’ Letter addressed to authorities).

15.20-15.40 Coffee break

Plenary Session 4
Hepatitis B therapy in the New Era
Chair: Ferruccio Bonino, Ioan Sporea

15.40-15.55 First line therapy for hepatitis B : nucleoside analogs (NUCs)
Marcel Tantau, Romania

15.55-16.15 The new dashboard for the individualized management of the HBV carrier
Ferruccio Bonino, Italy

16.15-16.30 Clinical applications of HBsAg quantification
Jerzy Jaroszewicz, Poland

16.30-16.45 When to stop NUCs
Oliviu Pascu, Romania

16.45-17.00 Impact of HBV therapy on long-term outcome of liver disease
Mircea Diculescu, Romania

17.00-17.20 Hepatitis delta: an update 2014
Liana Gheorghe, Romania

17.20-17.40 Discussion


Day 2 (Cirrhosis Day)
Managing Patients with Liver Cirrhosis

Plenary session 1
Assessment of pathophysiologic processes in liver diseases
Chair: Augusto Villanueva, Gabriel Becheanu, Monica Acalovschi

8.30-8.45 Non-invasive assessment of chronic liver disease
Annalisa Berzigotti, Spain

8.45-9.00 The role of pathology in diagnosis of liver disease
Elie Serge Zafrani, France

9.00-9.15 Molecular classification of hepatocellular carcinoma
Augusto Villanueva, UK

9.15-9.30 Gut microbiota and liver diseases
Razvan Iacob, Romania

9.30-9.50 Discussion

9.50-10.20 Coffee break

Plenary session 2
Complications of cirrhosis related to portal hypertension
Chair: Jaime Bosch, Cristian Gheorghe, Arun Sanyal

10.20-10.45 Acute variceal bleeding: risk, prevention and therapy
Jaime Bosch, Spain

10.45-11.00 Portal vein thrombosis and anti-coagulation in liver cirrhosis
Zeno Sparchez, Romania

11.00-11.15 Bacterial infections in cirrhosis
Dana Dobru, Romania

11.15-11.40 Hepatic encephalopathy
Arun Sanyal, USA

11.40-12.00 Discussion

12.00-13.30 Lunch, Ballroom foyer

12.00-13.00 Luncheon sessions with experts (limited places available)

Workshop 1
(30 places available)
Transilvania Room
Complications related to portal hypertension – management in current clinical practice
Chair: Jaime Bosch, Cristian Gheorghe

Workshop 2
(20 places available)
Moldova Room
Treating hepatocellular carcinoma in a multidisciplinary team
Chair: Fabio Piscaglia, Adina Croitoru

Plenary session 3
Liver cancer
Chair: Fabio Piscaglia, Ioana Lupescu, Adina Croitoru

13.30-13.45 Screening and diagnosis of HCC
Monica Acalovschi, Romania

13.45-14.05 Resection and transplantation for HCC
Irinel Popescu, Romania

14.05-14.20 Percutaneous ablation therapy for HCC
Fabio Piscaglia, Italy

14.20-14.55 Chemo and radioembolization for HCC
Mugur Grasu, Romania

14.35-14.50 Systemic therapy for HCC
Markus Peck-Radosavljevic, Austria

14.55-15.15 Discussion

15.15-15.35 Coffee break

Plenary session 4
Liver transplantation
Chair: Patrizia Burra, Irinel Popescu, Markus Peck-Radosavljevic

15.35-15.50 Correction of hereditary liver diseases by gene/cell therapy – current knowledge and future prospects
Michael Ott, Germany

15.50-16.05 Prophylaxis of HBV reinfection of the graft
Speranta Iacob, Romania

16.05-16.20 Treatment of HCV infection before and after liver transplantation
Liana Gheorghe, Romania

16.20-16.40 Long-term outcome and quality of life in liver transplant recipients
Patrizia Burra, Italy

16.40-17.05 Discussion

17.05-17.15 Closing remarks